Schwabing Hospital Release: New Phase III Study Confirms: Ginkgo Biloba Special Extract EGb 761® Significantly Improves Cognition and Neuropsychiatric Symptoms in Cognitive Disorders

KARLSRUHE, Germany--(BUSINESS WIRE)--Patients with neuropsychiatric symptoms resulting from mild to moderate vascular dementia, Alzheimer’s disease or mixed forms of dementia benefit from therapy with the Ginkgo biloba special extract EGb 761®. A new randomised, double-blind, placebo-controlled, multicentre study with 402 patients1 confirms this conclusion: Both cognition and behavioural problems improved significantly after 24 weeks. Although up to 80 percent of dementia patients suffer from neuropsychiatric symptoms 2,3 these are frequently excluded from dementia studies according to the author of the study, Prof. Horst Herrschaft, Cologne. For this reason, the current study findings are particularly valuable for everyday practice.